Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987–2001)

Williams, Laurel E.; Packer, Rebecca A.

doi:10.2460/javma.2003.222.1234

Cited by 159 publications

(150 citation statements)

References 8 publications

Supporting

Mentioning

128

Contrasting

Unclassified

Order By: Relevance

“…In dogs, the majority of oral melanomas have already metastasized by the time the lesion is noticed. 22 Evidence of vascular invasion and ipsilateral mandibular lymph node metastasis was present in both dogs in this study. Both dogs were treated for malignant melanoma.…”

mentioning

confidence: 68%

Gingival Osteogenic Melanoma in Two Dogs

et al. 2010

View full text Add to dashboard Cite

Abstract. Osteogenic melanoma is a rare variant of metaplastic malignant melanoma in human medicine and appears to be a similarly rare variant in dogs. Two dogs with oral malignant melanoma with neoplastic bone formation are reported in this study. Both tumors were characterized by malignant melanocytes that transitioned into neoplastic bone at the deep margins of the neoplasm. Immunohistochemical analysis revealed S100-and Melan-A-positive neoplastic cells adjacent to, and occasionally embedded within, an osteoid and chondroblastic matrix. Scattered clusters of neoplastic cells were also positive for osteocalcin. The findings indicate that in dogs, as in humans, neoplastic melanocytes have metaplastic potential and can be osteogenic.

show abstract

mentioning

confidence: 68%

Gingival Osteogenic Melanoma in Two Dogs

et al. 2010

View full text Add to dashboard Cite

show abstract

“…Therefore, the accuracy of diagnostic imaging for detecting disease progression is questionable. 58 However, this is a limitation for any type of biomarker-or imaging-based analysis. Rather than try to define de novo guidelines to assess clinical outcomes and disease progression based on pathology or imaging techniques, we propose close adherence to the standards established by RECIST, PERSIST, and Choi.…”

Section: Assessment Of Clinical Outcomesmentioning

confidence: 99%

Recommended Guidelines for the Conduct and Evaluation of Prognostic Studies in Veterinary Oncology

et al. 2010

View full text Add to dashboard Cite

There is an increasing need for more accurate prognostic and predictive markers in veterinary oncology because of an increasing number of treatment options, the increased financial costs associated with treatment, and the emotional stress experienced by owners in association with the disease and its treatment. Numerous studies have evaluated potential prognostic and predictive markers for veterinary neoplastic diseases, but there are no established guidelines or standards for the conduct and reporting of prognostic studies in veterinary medicine. This lack of standardization has made the evaluation and comparison of studies difficult. Most important, translating these results to clinical applications is problematic. To address this issue, the American College of Veterinary Pathologists' Oncology Committee organized an initiative to establish guidelines for the conduct and reporting of prognostic studies in veterinary oncology. The goal of this initiative is to increase the quality and standardization of veterinary prognostic studies to facilitate independent evaluation, validation, comparison, and implementation of study results. This article represents a consensus statement on the conduct and reporting of prognostic studies in veterinary oncology from veterinary pathologists and oncologists from around the world. These guidelines should be considered a recommendation based on the current state of knowledge in the field, and they will need to be continually reevaluated and revised as the field of veterinary oncology continues to progress. As mentioned, these guidelines were developed through an initiative of the American College of Veterinary Pathologists' Oncology Committee, and they have been reviewed and endorsed by the World Small Animal Veterinary Association.

show abstract

“…Fine needle aspiration and/or biopsy were used for preoperative tumor diagnosis. Cytology was the initial preoperative procedure adopted to clinically stage the palpable regional lymph nodes (LN), even in case of a not apparent clinicopathologic enlargement; in fact, size has not been considered sufficiently predictive (30). A more objective staging was achieved via the surgical removal of all palpable regional LN at the time of primary tumor resection and their full histologic evaluation.…”

Section: Dog Enrollmentmentioning

confidence: 99%

CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA

Riccardo¹,

Iussich

Maniscalco

et al. 2014

Clinical Cancer Research

View full text Add to dashboard Cite

Purpose: Due to the many similarities with its human counterpart, canine malignant melanoma (cMM) is a valuable model in which to assess the efficacy of novel therapeutic strategies. The model is herein used to evaluate the immunogenicity, safety, and therapeutic efficacy of a human chondroitin sulfate proteoglycan-4 (hCSPG4) DNA-based vaccine. The fact that homology between hCSPG4 and cCSPG4 amino-acidic sequences stands at more than 80% provides the rationale for using an hCSPG4 DNA vaccine in the cMM model.Experimental Design: Dogs with stage II-III surgically resected CSPG4-positive oral MM were subjected to monthly intramuscular plasmid administration, which was followed immediately by electroporation (electrovaccination) for at least 6, and up to 20, months. The immunogenicity, safety, and therapeutic efficacy of the vaccine have been evaluated.Results: hCSPG4 electrovaccination caused no clinically relevant local or systemic side effects and resulted in significantly longer overall and disease-free survival times in 14 vaccinated dogs as compared with 13 nonvaccinated controls. All vaccinated dogs developed antibodies against both hCSPG4 and cCSPG4. Seven vaccinated dogs were also tested for a cCSPG4-specific T-cell response and only two gave a detectable interferon (IFN)g response.Conclusion: Xenogeneic electrovaccination against CSPG4 is able to overcome host unresponsiveness to the "self" antigen and seems to be effective in treating cMM, laying the foundation for its translation to a human clinical setting.

show abstract

Association between lymph node size and metastasis in dogs with oral malignant melanoma: 100 cases (1987–2001)

Cited by 159 publications

References 8 publications

Gingival Osteogenic Melanoma in Two Dogs

Gingival Osteogenic Melanoma in Two Dogs

Recommended Guidelines for the Conduct and Evaluation of Prognostic Studies in Veterinary Oncology

CSPG4-Specific Immunity and Survival Prolongation in Dogs with Oral Malignant Melanoma Immunized with Human CSPG4 DNA

Contact Info

Product

Resources

About